Article citationsMore>>

T. Zima, V. Tesar, J. Crkovská, A. Stejskalová, J. Pláteník, J. Temínová, K. Nemecek, M. Janebová and S. Stípek, “ICRF-187 (Dexrazoxan) Protects from Adriamycin-Induced Nephrotic Syndrome in Rats,” Nephrology Dialysis Transplantation, Vol. 13, No. 8, 1998, pp. 1975-1979. http://dx.doi.org/10.1093/ndt/13.8.1975

has been cited by the following article:

• TITLE: Comparative Assessment of Melatonin-Afforded Protection in Liver, Kidney and Heart of Male Mice against Doxorubicin Induced Toxicity

  AUTHORS: Abdullah A. Alghasham

  KEYWORDS: Melatonin; Doxorubicin; Heart; Liver; Kidney; Lipidperoxidation; Non-Protein Sulfhydryls; Nitric Oxide; Plasma Enzymes; Mice

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.4 No.8, November 8, 2013

  ABSTRACT: Melatonin (MEL) was investigated for protection against the anthracycline antibiotic doxorubicin (Dox) that is well known for its oxidative damage to various body organs. It was aimed to have a comparison of this protection to heart, liver and kidney in the treated subjects. In this study, groups of mice were treated with Dox and melatonin and their individual or combined effects were evaluated by assessing lipidperoxidation, non-protein sulfhydryls (NP-SH) and nitrate/nitrite (NO) contents in these tissues. Plasma aminotransferases, LDH and CK-MB enzyme activities were measured. Moreover, these tissues were subject to histopathological assessment. MEL co-treatment significantly prevented any rise in lipidperoxides more significantly in heart and liver as compared to kidney. In tandem, MEL prevented a decline in GSH that was observed by Dox alone in liver and kidney. Dox significantly increased total NO levels in all the tissues. Melatonin at both dose levels could not afford protection against nitrosative stress. MEL in combination treatment provided significant (P